Related Experiment Video
Updated: Mar 8, 2026

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
Published on: March 7, 2025
Induced pluripotent stem cells as a cellular model for studying Down Syndrome
Anna Lisa Brigida1, Dario Siniscalco1
1Department of Experimental Medicine, Second University of Naples, 80138 Napoli, Italy.
Abstract:
Down Syndrome (DS), or Trisomy 21 Syndrome, is one of the most common genetic diseases. It is a chromosomal abnormality caused by a duplication of chromosome 21. DS patients show the presence of a third copy (or a partial third copy) of chromosome 21 (trisomy), as result of meiotic errors. These patients suffer of many health problems, such as intellectual disability, congenital heart disease, duodenal stenosis, Alzheimer's disease, leukemia, immune system deficiencies, muscle hypotonia and motor disorders. About one in 1000 babies born each year are affected by DS. Alterations in the dosage of genes located on chromosome 21 (also called HSA21) are responsible for the DS phenotype. However, the molecular pathogenic mechanisms of DS triggering are still not understood; newest evidences suggest the involvement of epigenetic mechanisms. For obvious ethical reasons, studies performed on DS patients, as well as on human trisomic tissues are limited. Some authors have proposed mouse models of this syndrome. However, not all the features of the syndrome are represented. Stem cells are considered the future of molecular and regenerative medicine. Several types of stem cells could provide a valid approach to offer a potential treatment for some untreatable human diseases. Stem cells also represent a valid system to develop new cell-based drugs and/or a model to study molecular disease pathways. Among stem cell types, patient-derived induced pluripotent stem (iPS) cells offer some advantages for cell and tissue replacement, engineering and studying: self-renewal capacity, pluripotency and ease of accessibility to donor tissues. These cells can be reprogrammed into completely different cellular types. They are derived from adult somatic cells via reprogramming with ectopic expression of four transcription factors (Oct3/4, Sox2, c-Myc and Klf4; or, Oct3/4, Sox2, Nanog, and Lin28). By reprogramming cells from DS patients, it is possible to obtain new tissue with the same genetic background, offering a valuable tool for studying this genetic disease and to design customized patient-specific stem cell therapies.
Insights
Down Syndrome (DS), a genetic disorder caused by Trisomy 21, leads to numerous health issues. Patient-derived induced pluripotent stem cells offer a promising model for studying DS and developing personalized therapies.
Area of Science:
- Genetics
- Stem Cell Biology
- Developmental Biology
Background:
- Down Syndrome (DS), or Trisomy 21, is a common genetic disorder resulting from an extra copy of chromosome 21.
- DS is associated with a wide range of health problems, including intellectual disability, congenital heart disease, and increased risk for leukemia and Alzheimer's disease.
- The precise molecular mechanisms underlying DS pathogenesis remain unclear, with emerging evidence pointing towards epigenetic factors.
Approach:
- Utilizing patient-derived induced pluripotent stem (iPS) cells as a model system to study Down Syndrome.
- Reprogramming adult somatic cells from DS patients into iPS cells, maintaining their genetic background.
- Investigating the potential of iPS cells for developing cell-based therapies and drug discovery for DS.
Key Points:
- iPS cells possess self-renewal capacity and pluripotency, making them versatile for regenerative medicine.
- Patient-derived iPS cells provide a genetically matched platform for studying disease mechanisms.
- This approach facilitates the development of customized, patient-specific stem cell therapies for Down Syndrome.
Conclusions:
- Induced pluripotent stem cells derived from Down Syndrome patients represent a powerful tool for understanding the disease.
- These patient-specific iPS cells can advance research into the molecular pathways of DS.
- The use of iPS cells holds significant promise for future therapeutic strategies and personalized medicine in Down Syndrome.
More Related Videos
09:39Generation of Induced Pluripotent Stem Cells from Turner Syndrome 45XO Fetal Cells for Downstream Modelling of Neurological Deficits Associated with the Syndrome
Published on: December 4, 2021
09:11Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
Published on: January 28, 2015
Related Concept Videos
EPS and iPS Cells in Disease Research
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
iPS Cell Differentiation